NCT03347032

Remote Ischemic Preconditioning for Renal Protection in TAVI

Completed NA Last updated 14 December 2022

What this trial tests

NA trial testing Remote ischemic preconditioning in Aortic Valve Stenosis in 46 participants. Completed in 30 December 2018.

Timeline

13 February 2018

Primary endpoint
30 December 2018

30 December 2018

Quick facts

Lead sponsor	Henry Ford Health System
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	46
Start date	13 February 2018
Primary completion	30 December 2018
Estimated completion	30 December 2018
Sites	1 location across United States

Drugs / interventions tested

• Remote ischemic preconditioning
• Control

Conditions studied

• Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
• Renal Insufficiency — all drugs for Renal Insufficiency →
• Contrast-induced Nephropathy — all drugs for Contrast-induced Nephropathy →

Sponsor

Henry Ford Health System — full company profile →

Who can join

18 and older, any sex, with Aortic Valve Stenosis or Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Severe aortic stenosis remains a major cause of morbidity and mortality of the elderly affecting approximately 3% of elderly patients with an increasing number of patients undergoing transcatheter aortic valve interventions. As part of pre-procedural planning these patients undergo CT scans and receive contrast during the procedure. These patients often have baseline renal insufficiency and are high risk of contrast induced nephropathy despite pre-hydration techniques. The purpose of this study is to evaluate the efficacy of this simple and safe procedure in preventing renal injury in this particular population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.